Pharmacyte Biotech Inc (OTCMKTS:PMCB), a leading clinical stage biotech company is delighted to announce that its senior management executives have been featured in a well-known magazine. According to a report, company’s COO Dr. Gerald W. Crabtree, Ph.D. and CEO Kenneth L. Waggoner, JD, have made it to PharmaVOICE Magazine‘s September edition.
Insights On The Matter
Both the senior business leaders of Pharmacyte shared their views on the role of business leaders in oncology for developing clinical trials. Their views have been published in an article titled “Oncology KOLS: An Important Piece of the Puzzle.”
Dr. Gerald W. Crabtree, Ph.D. stated that Pharmacyte is one of those very few companies in the world that focuses on involving thought leaders in diabetes and oncology areas for all the clinical development programs. Under the guidance of these business leaders, the road to achieving greatness and excellent trial results becomes very easy and hassle-free for the company.
Adding to his statement, Kenneth L. Waggoner mentioned that the company relies on the expertise of its three world-famous oncologists to develop and design trials for the patients suffering from pancreatic cancer. Their guidance has helped the company finish its trials and achieve positive results in trials focusing on pancreatic cancer and other life-threatening diseases.
USANA Health Sciences, Inc. (NYSE:USNA) has once again proved its efficiency and fast paced working strategy in front of the entire world. According to a report, the company has been named as one of the top fifty companies in the state of Utah in terms of growth. It’s the 8th straight year when the company has made it to this list.
Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has started preparing to uplist on NASDAQ marketplace. As part of its strategy, the company has announced a reverse stock split in the format of one post-consolidated common Share for every ten pre-consolidated Shares of the company.
